The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …

Background Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting
risk of reinfection and durability of vaccine protection. Methods This is a prospective, …

We investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies and T-cell responses against SARS-CoV-2 and human coronavirus (HCoV) 229E …

Background The serologic response of individuals with mild forms of SARS-CoV-2 infection
is poorly characterized. Methods Hospital staff who had recovered from mild forms of PCR-…

The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India 1 – 6 . It has since then
become dominant in some indian regions and further spread to many countries. The …

We measured anti-spike (S), nucleoprotein (N), and neutralizing antibodies in sera from 308
healthcare workers with a positive reverse-transcription quantitative polymerase chain …

The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against
the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we …

To the editor: Immunocompromised patients show an impaired vaccine-induced immune
response, resulting in an increased risk of severe coronavirus disease 2019 (COVID-19). 1 In …

BK virus–associated nephropathy (BKVAN) causes renal allograft dysfunction. The current
management of BKVAN relies on pre-emptive adaptation of immunosuppression according to …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …